School of Medicine, Faculdade de Medicina de Botucatu-UNESP, Botucatu, SP, Brazil.
Departamento de Clínica Médica, Faculdade de Medicina de Botucatu-UNESP, Botucatu, SP, Brazil.
Int Urol Nephrol. 2023 Jun;55(6):1501-1508. doi: 10.1007/s11255-022-03454-4. Epub 2022 Dec 30.
Acute kidney injury (AKI) is one of the main complications of COVID-19 caused by SARS-CoV-2. This study aimed to evaluate the incidence of AKI in Brazilian hospitalized patients diagnosed with COVID-19 and identify the risk factors associated with its onset and those associated with its prognosis.
A prospective cohort study of hospitalized patients diagnosed with COVID-19 at a public and tertiary university hospital in São Paulo from March to December 2020.
There were 347 patients hospitalized with COVID-19, 52.4% were admitted to the intensive care unit (ICU) and 47.6% were admitted to the wards. The overall incidence of AKI was 46.4%, more frequent in the ICU (68.1% vs 22.4, p < 0.01) and the overall mortality was 36.1%. Acute kidney replacement therapy was indicated in 46.6% of patients with AKI. In the general population, the factors associated with AKI were older age (OR 1.03, CI 1-1.05, p < 0.05), mechanical ventilation (OR 1.23, CI 1.06-1.83, p < 0.05), presence of proteinuria (OR 1.46, CI 1.22-1.93, p < 0.05), and use of vasoactive drugs (OR 1.26, CI 1.07-1.92, p < 0.05). Mortality was higher in the elderly (OR 1.08, CI 1.04-1.11, p < 0.05), in those with AKI (OR 1.12, CI 1.02-2.05, p < 0.05), particularly KDIGO stage 3 AKI (OR 1.10, CI 1.22-2.05, p < 0.05) and in need of mechanical ventilation (OR 1.13, CI 1.03-1.60, p < 0.05).
AKI was frequent in hospitalized patients with COVID-19 and the factors associated with its development were older age, mechanical ventilation, use of vasoactive drugs, and presence of proteinuria, being a risk factor for death.
急性肾损伤(AKI)是由 SARS-CoV-2 引起的 COVID-19 的主要并发症之一。本研究旨在评估巴西住院 COVID-19 患者 AKI 的发生率,并确定与 AKI 发病和预后相关的危险因素。
这是一项前瞻性队列研究,纳入了 2020 年 3 月至 12 月期间在圣保罗一家公立三级大学医院住院的 COVID-19 患者。
共有 347 例 COVID-19 住院患者,52.4%入住重症监护病房(ICU),47.6%入住病房。AKI 的总体发生率为 46.4%,ICU 中更为常见(68.1% vs 22.4%,p<0.01),总体死亡率为 36.1%。AKI 患者中有 46.6%需要进行急性肾脏替代治疗。在一般人群中,AKI 的相关因素为年龄较大(OR 1.03,CI 1-1.05,p<0.05)、机械通气(OR 1.23,CI 1.06-1.83,p<0.05)、蛋白尿(OR 1.46,CI 1.22-1.93,p<0.05)和血管活性药物的使用(OR 1.26,CI 1.07-1.92,p<0.05)。年龄较大(OR 1.08,CI 1.04-1.11,p<0.05)、AKI 患者(OR 1.12,CI 1.02-2.05,p<0.05)、尤其是 KDIGO 3 期 AKI(OR 1.10,CI 1.22-2.05,p<0.05)和需要机械通气(OR 1.13,CI 1.03-1.60,p<0.05)的患者死亡率更高。
COVID-19 住院患者中 AKI 较为常见,其发病的相关因素为年龄较大、机械通气、血管活性药物的使用和蛋白尿,是死亡的危险因素。